Announcements Trials

Browse Landscape

Phase

Status

Completed 7 Recruiting 2 Active not recruiting 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Diarrhea 3 Prostatic Neoplasms 2 Neoplasms 2 Breast Neoplasms 2 Vipoma 1 Somatostatinoma 1 Serotonin Syndrome 1 Recurrence 1 Rectal Neoplasms 1 Pheochromocytoma 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Lymphocele 1 Intestinal Obstruction 1 Insulinoma 1 Head and Neck Neoplasms 1 Glucagonoma 1 Gastro-enteropancreatic neuroendocrine tumor 1 Gastrinoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Medullary 1 Carcinoma, Islet Cell 1 Adenoma, Islet Cell 1 Adenoma 1 Acromegaly 1

Interventions

Everolimus 7 lutetium Lu 177 dotatate 3 Erlotinib Hydrochloride 3 surufatinib 2 gallium Ga 68 dotatate 2 dactolisib 2 Sunitinib 2 Magnetic Resonance Spectroscopy 2 trifluridine tipiracil drug combination 1 tislelizumab 1 telotristat ethyl 1 telotristat 1 pertuzumab 1 pembrolizumab 1 pelcitoclax 1 pegfilgrastim 1 lanreotide 1 fosbretabulin 1 entinostat 1 arginyllysine 1 amino-acid, glucose, and electrolyte solution 1 alectinib 1 Temozolomide 1 Surveys and Questionnaires 1 Somatostatin 1 Serotonin 1 Quality of Life 1 Positron Emission Tomography Computed Tomography 1 Panobinostat 1 Oxaliplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neuroendocrine Tumors × Octreotide × Clear all

NCT04140409 2019-10-25

SCIROCCO

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Phase 4 Terminated

Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡